Crossmark

Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?

Crossref DOI link: https://doi.org/10.1038/s41409-020-01099-4

Published Online: 2020-11-10

Published Print: 2021-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ghafouri, Sanaz https://orcid.org/0000-0002-1610-220X
Timmerman, John

Larson, Sarah

Mead, Monica D.
License Information

Text and Data Mining valid from 2020-11-10

Version of Record valid from 2020-11-10
More Information

Article History

Received: 8 September 2020

Accepted: 20 October 2020

First Online: 10 November 2020

Compliance with ethical standards

:

: SG and MM have no conflict of interest. JT received research funding form BMS, Kite, ImmunGene. SL is consultant for BMS.

Document is current

Any future updates will be listed below